RealFeedApp Nurix shares drop more than 40% in early trading
Sanofi has stopped the development of oral drug SAR448272, which targets the protein STAT6 involved in inflammation. The decision was based on emerging nonclinical findings, causing company shares to drop over 40%.
- Field
- drugs and trials
- What they did
- Sanofi has halted the development of an experimental drug called SAR448272, which is designed to degrade the protein STAT6 involved in inflammation.
- Why it matters
- The company cited emerging nonclinical findings that did not justify further development of the treatment, a decision that caused the company's stock to drop significantly.
#sanofi#nurix#stat6#protein degrader#clinical trial
